Liposarcoma malady

NIH Rare Diseases: Liposarcoma is a tumor that arises from fat tissue.  This tumor often occurs in the thigh, behind the knee, or in the abdomen, but it can be found in other parts of the body.  Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor.³⁰

MalaCards: Liposarcoma, also known as liposarcoma nos (morphologic abnormality), is related to pleomorphic liposarcoma and lipoma. An important gene associated with Liposarcoma is FUS (fused in sarcoma), and among its related pathways are Colorectal cancer and Akt Signaling. The compounds egcg and sp 600125 have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, adipocyte and thyroid, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

Disease Ontology: A malignant lipomatous neoplasm that arises in fat cells in deep soft tissue retroperitoneum.⁶

Wikipedia: Liposarcoma is a malignant tumor that arises in fat cells in deep soft tissue, such as that inside the...⁴⁴ more...

Aliases & Descriptions:

liposarcoma 6 7 30 8 33 32 43 liposarcoma nos (morphologic abnormality) 6

liposarcoma (morphologic abnormality) 6 liposarcoma (disorder) 6

Diseases related to liposarcoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 781)

id	Related Disease	Score	Top Affiliating Genes
1	pleomorphic liposarcoma	33.5	KIT, MDM2, NOS2
2	lipoma	32.2	LRP1, VIM, FUS, CDKN2A, CD34, CDK4
3	myxoid liposarcoma of the ovary	31.6	ATF1, FUS, CDK4, MDM2, EWSR1, ERG
4	fibrous histiocytoma	31.1	VIM, ATF1, FUS, CD34, F13A1, ACTC1
5	atypical lipomatous tumor	30.8	CDKN2A, CDK4, MDM2, HMGA2, PLAG1
6	retroperitoneal sarcoma	28.6	CDK4, MDM2, PPARG, TYR
7	spindle cell lipoma	28.6	VIM, CD34, CDK4, MDM2, ACTC1, DES
8	pleomorphic adenoma	28.2	VIM, MUC1, MDM2, HMGA2, TNC, PLAG1
9	synovial sarcoma	27.9	KIT, VIM, RARA, BCL2, MUC1, FLI1
10	hemangiopericytoma	27.8	RB1, VIM, VEGFA, KDR, MUC1, CD34
11	breast cancer	27.3	S100A4, CDK2, CDK4, FASN, TNC, NR1H2
12	malignant fibrous histiocytoma	27.0	RB1, VIM, VEGFA, LPL, BCL2, MVP
13	angiomyolipoma	26.9	KIT, RB1, VIM, MUC1, CDKN2A, IL6
14	histiocytoma	26.8	RB1, VIM, VEGFA, LPL, BCL2, MVP
15	leukemoid reaction	26.7	IL3, CRP, CSF3
16	leiomyosarcoma	25.4	KIT, RB1, VIM, VEGFA, BCL2, MVP
17	fibrosarcoma	25.2	KIT, RB1, VIM, VEGFA, PARP1, KDR
18	renal cell carcinoma	25.1	RELA, RET, KIT, VIM, VEGFA, KDR
19	soft tissue sarcoma	24.3	KIT, RB1, VIM, VEGFA, RARA, KDR
20	acute myeloid leukemia	22.3	RELA, KIT, RB1, VEGFA, RARA, PARP1
21	myeloid leukemia	21.9	RELA, KIT, RB1, VIM, VEGFA, RARA
22	osteosarcoma	20.6	RELA, KIT, RB1, VIM, VEGFA, LPL
23	sarcoma	20.3	RELA, RET, KIT, RB1, VIM, VEGFA
24	cholesterol	20.0	LRP1, LRPAP1, RELA, RB1, VIM, VEGFA
25	fibrosis	18.5	LRP1, RELA, KIT, VIM, VEGFA, LPL
26	adenoma	18.1	RET, KIT, RB1, VIM, VEGFA, RARA
27	colorectal cancer	17.9	LRPAP1, RET, KIT, RB1, VIM, VEGFA
28	leukemia	17.1	LRP1, LRPAP1, RELA, KIT, RB1, VIM
29	thyroiditis	16.5	LRP1, LRPAP1, RELA, RET, KIT, RB1
30	carcinoma	14.9	LRP1, LRPAP1, RELA, RET, KIT, RB1
31	kidney clear cell sarcoma	14.1	KIT, ATF1, FUS, EWSR1
32	chondroma	14.1	KIT, CDK4, MDM2, HMGA2, TSPAN31
33	ring chromosomes	14.1	CDK4, MDM2, EWSR1, HMGA2, CREB3L2, PLAG1
34	alveolar rhabdomyosarcoma	14.1	RB1, VIM, MDM2, TSN, DES
35	meninges sarcoma	14.1	VIM, MB, DES
36	retinal detachment	14.0	VIM, VEGFA, LEPREL1, IL6, CCL2, NOS2
37	endometrial stromal sarcoma	14.0	KIT, VIM, INHA, ACTC1, DES
38	adenosarcoma	14.0	KIT, MB, CALB2, ACTC1, DES
39	orbit embryonal rhabdomyosarcoma	14.0	CDK4, MB, EWSR1, ACTC1, DES
40	ewing's family of tumors	14.0	VIM, CDK4, EWSR1, TNC
41	sex cord-gonadal stromal tumor	14.0	VIM, INHA, CALB2
42	ossifying fibromyxoid tumor	14.0	VIM, CREB3L2, ACTC1, DES
43	glomangiomyoma	14.0	VIM, ACTC1, DES
44	infantile myofibromatosis	14.0	VIM, ACTC1, DES
45	bronchopulmonary dysplasia	14.0	VEGFA, FLT1, MIF, IL6, IL8, CCL2
46	mixed epithelial stromal tumour	14.0	INHA, CALB2, DES
47	myofibroma	13.9	VIM, ACTC1, DES
48	cutaneous fibrous histiocytoma	13.9	VIM, CD34, F13A1, DES
49	meninges hemangiopericytoma	13.9	RB1, VIM, MUC1, DES
50	placental insufficiency	13.9	FLT1, IL6, IL8, CALB2, PGF, AFP

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to liposarcoma:

²²

MGI Mouse Phenotypes related to liposarcoma:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.3	THRA, TYR, HMGA2, EWSR1, INHA, FUS
2	respiratory system phenotype	MP:0005388	10.2	PGF, POLR2A, SMARCA4, TRPA1, F13A1, MB
3	craniofacial phenotype	MP:0005382	10.1	THRA, RXRA, CREB3L2, HMGA2, CASP9, YBX1
4	embryogenesis phenotype	MP:0005380	9.7	CASP9, MB, MDM2, FLI1, CDK4, ATF1
5	no phenotypic analysis	MP:0003012	9.3	ATF6, TP53, PPARG, TYR, TARDBP, CEBPB
6	liver/biliary system phenotype	MP:0005370	9.1	VEGFA, KIT, TP53, CCND2, IL6, FLI1
7	hematopoietic system phenotype	MP:0005397	9.0	WNT1, POLR2A, CSF3, PRKG1, TSN, FLI1
8	limbs/digits/tail phenotype	MP:0005371	9.0	TERC, SMARCA4, CREB3L2, RXRA, TYR, THBS1
9	behavior/neurological phenotype	MP:0005386	8.7	PRRX1, NR1H3, PPARG, DDIT3, TERC, TNC
10	normal phenotype	MP:0002873	8.7	NR1H2, TNC, TRPA1, EWSR1, CALB2, NR1H3
11	hearing/vestibular/ear phenotype	MP:0005377	8.6	TRPA1, TNC, PPARG, RXRA, THRA, PRRX1
12	adipose tissue phenotype	MP:0005375	8.6	PPARA, PPARG, TERC, TP53, NR3C1, NOS2
13	immune system phenotype	MP:0005387	8.6	SMARCA4, NR3C1, PPARA, DDIT3, PTX3, TERC
14	pigmentation phenotype	MP:0001186	8.4	TYR, RXRA, TERC, TP53, CASP3, CCL2
15	renal/urinary system phenotype	MP:0005367	8.3	EWSR1, SMARCA4, RXRA, PDGFA, TYR, THBS1
16	reproductive system phenotype	MP:0005389	8.2	TYR, PDGFA, RXRA, NOS2, PLAG1, NR1H3
17	nervous system phenotype	MP:0003631	8.1	FLI1, RARA, RB1, KIT, RELA, LRPAP1
18	integument phenotype	MP:0010771	7.9	TP53, TRPA1, HMGA2, EWSR1, FAS, MDM2
19	skeleton phenotype	MP:0005390	7.7	WNT1, PRRX1, PRG4, THRA, THBS1, TYR
20	tumorigenesis	MP:0002006	7.6	AFP, EWSR1, CCL2, FAS, MDM2, IL6
21	digestive/alimentary phenotype	MP:0005381	7.3	MDM2, INHA, MLH1, CDKN2A, CD36, MSH2
22	mortality/aging	MP:0010768	6.9	AFP, NOS2, CREB3L2, SMARCA4, NR3C1, NR1H3
23	vision/eye phenotype	MP:0005391	6.8	PGF, CASP3, CCND2, CCL2, FAS, IL6
24	muscle phenotype	MP:0005369	6.6	RELA, LRP1, RET, SMARCA4, NR1H3, NR1H2
25	growth/size phenotype	MP:0005378	6.4	SLC2A4, POLR2A, PRRX1, TARDBP, TERC, TP53
26	cellular phenotype	MP:0005384	5.2	RET, RELA, KIT, PPARG, FAS, MDM2
27	cardiovascular system phenotype	MP:0005385	5.2	PGF, SLC2A4, CXCL12, PRRX1, PRG4, VIM
28	homeostasis/metabolism phenotype	MP:0005376	2.5	CASP3, MIF, FLT1, MLH1, CDK4, CD34

Articles related to liposarcoma:

(show top 50)    (show all 148)

id	Title	Authors	Year	Affiliating Genes
1	Well-differentiated and dedifferentiated liposarcomas . (19688222)	Coindre J.M.... Aurias A.	2010	MDM2
2	Fatty acid synthesis is a therapeutic target in human liposarcoma. (20372807)	Olsen A.M.... Kinlaw W.B.	2010	ACACA
3	Nuclear expression of FLT1 and its ligand PGF in FUS- DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine sign aling loop. (20515481)	Andersson M.K.... Aman P.	2010	FLT1, PGF
4	Clinical and biological significance of CDK4 amplific ation in well-differentiated and dedifferentiated liposarcomas. (19737942)	Italiano A.... Pedeutour F.	2009	CDK4, MDM2, HMGA2
5	HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. (18214854)	Italiano A.... Pedeutour F.	2008	CDK4, MDM2, DDIT3
6	Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. (18204431)	Horvai A.E.... O'Donnell R.J.	2008	CDK4, MDM2, PPARG
7	Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. (18497564)	Dass C.R.... Choong P.F.	2008	JUN, CASP10
8	High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. (18414473)	Cairney C.J.... Keith W.N.	2008	TERC
9	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. (17638873)	Singer S.... Antonescu C.R.	2007	MDM2
10	Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the 'missing link' between lipomas and liposarcomas? (17372913)	Italiano A.... Pedeutour F.	2007	CDK4, MDM2, HMGA2
11	Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. (17468515)	Perez-Mancera P.A.... Sanchez-Garcia I.	2007	FUS, DDIT3
12	Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. (17895758)	Binh M.B.... Coindre J.M.	2007	CDK4, MDM2, DES
13	Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. (17647282)	Bode-Lesniewska B.... Zimmermann D.R.	2007	DDIT3, EWSR1
14	Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSF-producing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage. (18021394)	Sakamoto A.... Iwamoto Y.	2007	IL3, CSF3
15	Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. (17214366)	Segura-SA!nchez J.... LA^pez-BeltrA!n A.	2006	CDK4, MDM2
16	The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. (16651630)	Engstrom K.... Aman P.	2006	FUS, DDIT3
17	Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas (15796878)	Xiang H.... Zhu X.Z.	2005	PRKG1, FUS
18	Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. (15688424)	Goransson M.... Aman P.	2005	IL6, FUS, DDIT3
19	Uterine liposarcoma in a young woman: a case report. (16343221)	Karateke A.... Cetiner H.	2005	MUC1
20	Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. (14694526)	Hostein I.... Coindre J.M.	2004	CDK4, MDM2
21	Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. (15514255)	Wassef H.... Cohn J.S.	2004	APOC1
22	RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. (12168660)	Rapp T.B.... Chansky H.A.	2002	POLR2A, FUS, DDIT3
23	The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. (11604390)	Vassiliou G.... McPherson R.	2001	LRP1, LRPAP1
24	Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. (11351297)	Tamborini E.... Pilotti S.	2001	MDM2
25	Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. (11480734)	Ylagan L.R.... Bhalla S.	2001	DES, ACTC1
26	Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. (11369052)	Forus A.... Myklebost O.	2001	CDK4, MDM2, HMGA2
27	Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. (11518050)	Boltze C.... Roessner A.	2001	MDM2
28	Morphologic-cytogenetic analysis of dedifferentiated liposarcomas with an extensive misleading leiomyosarcomatous component. (10981874)	Pilotti S.... Pierotti M.A.	2000	DES
29	The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. (10755400)	Pilotti S.... Pierotti M.A.	2000	CDK4, MDM2
30	Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;6). (11126370)	Hosaka T.... Toguchida J.	2000	DDIT3, TSN
31	Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. (11229517)	Antonescu C.R.... Ladanyi M.	2000	FUS, DDIT3
32	The 16p11 breakpoint in myxoid liposarcomas might affect the expression of the LRP gene on 16p11.2 encoding the multidrug resistance associated major vault protein. (10809905)	Plaat B.E.... van den Berg E.	2000	MVP
33	Myxoid liposarcoma with transition to round-cell lesion-cell cycle regulator genes and telomerase activity characterizing tumor progression: a case report. (10667432)	Jaeger V.... Roessner A.	1999	SMARCA4
34	Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. (10449603)	Thelin-Jaernum S.... Aaman P.	1999	LEPREL1, NNAT
35	Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation. (9989822)	Kanoe H.... Toguchida J.	1999	FUS, DDIT3, TSN
36	Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. (9713346)	Pilotti S.... Pierotti M.A.	1998	CDK4, MDM2
37	Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. (9624148)	Adelmant G.... Freytag S.O.	1998	DDIT3
38	Liposarcoma with meningothelial-like whorls: a study of 17 cases of a distinctive histological pattern associated with dedifferentia ted liposarcoma. (9839165)	Fanburg-Smith J.C.... Miettinen M.	1998	MUC1
39	Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications. (9676855)	Willeke F.... von Knebel Doeberitz M.	1998	FUS, DDIT3
40	Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia. (9315104)	Panagopoulos I.... Aman P.	1997	DDIT3, EWSR1
41	Fibrohistiocytic differentiation in subcutaneous fatty tumors. Study of spindle cell, pleomorphic, myxoid, and atypical lipoma and dedifferentiated liposarcoma cases composed in part of CD34+ fibroblasts and FXIIIa+ histiocytes. (9331894)	Silverman J.S.... Tamsen A.	1997	DES
42	Dedifferentiated liposarcoma with an inflammatory malignant fibrous histiocytoma-like component presenting a leukemoid reaction. (9311018)	Hisaoka M.... Uriu K.	1997	CRP
43	Fusion of the EWS and CHOP genes in myxoid liposarcoma. (8637704)	Panagopoulos I.... Aman P.	1996	FUS, DDIT3, EWSR1
44	Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). (7566973)	Panagopoulos I.... Aman P.	1995	FUS, DDIT3, ERG
45	Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. (7805034)	Knight J.C.... Fletcher C.D.	1995	FUS, DDIT3
46	Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. (8510758)	Crozat A.... Ron D.	1993	FUS, DDIT3, NR1H3
47	Identification of glucagon receptors in human adipocytes from a liposarcoma. (8396602)	Carranza M.C.... Calle C.	1993	GCGR
48	Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). (1283316)	Aman P.... Mitelman F.	1992	DDIT3
49	Putative apolipoprotein receptor gene (LRP, A2MR) is not rearranged in either myxoid liposarcoma or lipomas with translocations in 12q13-14. (1318779)	Paulien S.... Gemmill R.M.	1992	LRP1
50	Localization of the chromosomal breakpoints of the t(12;16) in liposarcoma to subbands 12q13.3 and 16p11.2. (2372777)	Eneroth M.... Mitelman F.	1990	FUS, DDIT3

Genes related to liposarcoma according to GeneCards:

(show top 50)    (show all 133)

id	Symbol	Description	Score	GeneCards Section Context
1	FUS	fused in sarcoma	11.1	Functions, Publications, Aliases & Descriptions, Orthologs
2	DDIT3	DNA-damage-inducible transcript 3	11.1	Publications, Summaries
3	HMGA2	high mobility group AT-hook 2	11.1	Summaries, Publications
4	LEPREL1	leprecan-like 1	11.0	Aliases & Descriptions, Publications
5	LPSA	Oncogene liposarcoma (DNA segment, single copy, expressed, probes	11.0	Aliases & Descriptions, Disorders
6	MDM2	Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse)	11.0	Publications, Functions
7	CDK4	cyclin-dependent kinase 4	11.0	Publications
8	EWSR1	Ewing sarcoma breakpoint region 1	11.0	Publications
9	DES	desmin	11.0	Publications
10	TSN	translin	11.0	Publications
11	POLR2L	polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa	11.0	Publications
12	ATF1	activating transcription factor 1	11.0
13	MVP	major vault protein	11.0	Publications
14	CALB2	calbindin 2	11.0	Publications
15	YBX1	Y box binding protein 1	11.0	Publications
16	LRP1	low density lipoprotein receptor-related protein 1	11.0	Publications
17	RB1	retinoblastoma 1	11.0	Publications
18	PPARG	peroxisome proliferator-activated receptor gamma	11.0	Publications, Technologies
19	ERG	v-ets erythroblastosis virus E26 oncogene homolog (avian)	11.0	Publications
20	VIM	vimentin	11.0	Publications
21	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	11.0
22	NNAT	neuronatin	11.0	Publications
23	C6orf108	chromosome 6 open reading frame 108	11.0
24	NFKBIZ	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta	11.0	Publications
25	PRG4	proteoglycan 4	11.0	Publications
26	PTX3	pentraxin 3, long	11.0	Publications
27	ADAD1	adenosine deaminase domain containing 1 (testis-specific)	11.0	Publications
28	WNT1	wingless-type MMTV integration site family, member 1	11.0	Publications
29	INHA	inhibin, alpha	11.0	Publications
30	NR1H3	nuclear receptor subfamily 1, group H, member 3	11.0	Publications
31	PDGFA	platelet-derived growth factor alpha polypeptide	11.0	Publications
32	PGF	placental growth factor	11.0	Publications
33	TERC	telomerase RNA component	11.0	Publications
34	CEBPB	CCAAT/enhancer binding protein (C/EBP), beta	11.0	Publications
35	CREB3L2	cAMP responsive element binding protein 3-like 2	11.0
36	MIF	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	11.0	Publications
37	SMARCA4	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	11.0	Publications
38	TARDBP	TAR DNA binding protein	11.0
39	POLR2A	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa	11.0	Publications
40	FLI1	Friend leukemia virus integration 1	11.0
41	DUSP19	dual specificity phosphatase 19	11.0	Publications
42	CD34	CD34 molecule	11.0
43	CETP	cholesteryl ester transfer protein, plasma	11.0	Publications
44	MB	myoglobin	11.0	Publications
45	TNC	tenascin C	11.0
46	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)	11.0	Publications
47	RARA	retinoic acid receptor, alpha	11.0
48	CCL2	chemokine (C-C motif) ligand 2	11.0	Publications
49	CXCL12	chemokine (C-X-C motif) ligand 12	11.0	Publications
50	PPARA	peroxisome proliferator-activated receptor alpha	11.0	Publications

Pathways related to liposarcoma according to GeneDecks:

(show top 50)    (show all 135)

id	Pathway	Score	Top Affiliating Genes
1	Colorectal cancer20	10.6	MSH2, CASP9
2	Akt Signaling36	10.5	PGF, CCL2, CXCL12, PDGFA, MDM2, IL6
3	ERK Signaling36	10.3	CSF3, CXCL12, PRG4, KIT, ATF1, IL3
4	Immune response MIF-mediated glucocorticoid regulation10	10.2	MIF, JUN, RELA, IL6, NOS2, NR3C1
5	Immune response_MIF-mediated glucocorticoid regulation41	10.2	IL8, NOS2, NR3C1, IL6, MIF, JUN
6	Endothelin-1 Signaling Pathway36	10.1	CSF3, CXCL12, CASP3, IL6, IL3, FLT1
7	Nuclear Receptor Activation by Vitamin-A36	10.1	IL3, POLR2A, PDGFA, CXCL12, KIT, KDR
8	Bladder cancer20	10.0	IL8, CDK4, VEGFA, RB1, CDKN2A, MDM2
9	ILK Signaling36	10.0	KIT, CASP9, TNC, PGF, IL3, JUN
10	Immune response MIF-JAB1 signaling10	9.9	JUN, NR3C1, CCND2, MIF, CDK4, CDK2
11	Immune response_MIF-JAB1 signaling41	9.9	CDK2, RELA, NR3C1, CCND2, MIF, CDK4
12	Telomerase Components in Cell Signaling36	9.9	RB1, CXCL12, KIT, POLR2A, TP53, KDR
13	Immune response MIF in innate immunity response10	9.9	IL6, MIF, CEBPB, TP53, JUN, NOS2
14	Immune response_MIF in innate immunity response41	9.9	IL8, IL6, CEBPB, RELA, JUN, MIF
15	Cell cycle_Regulation of G1/S transition (part 2)41	9.8	RELA, RB1, JUN, CCND2, CDK2, CDK4
16	Transcription P53 signaling pathway10	9.8	RELA, VEGFA, CDK2, TP53, CDKN2A
17	Malaria20	9.6	CSF3, IL8, THBS1, CCL2, LRP1, CD36
18	Small cell lung cancer20	9.5	CDK2, TP53, CDK4, BCL2, RB1, RXRA
19	Apoptosis and survival Lymphotoxin-beta receptor signaling10	9.5	JUN, BAX, CXCL12, RELA, IL8, CASP9
20	Prostate cancer20	9.5	BCL2, CDK2, TP53, CASP9, RB1, RELA
21	Cell cycle Regulation of G1/S transition (part 2)10	9.5	CDK4, CCND2, CDK2, JUN, RB1, RELA
22	Apoptosis and survival_Lymphotoxin-beta receptor signaling41	9.4	RELA, BAX, IL8, CASP3, CASP9, CXCL12
23	Proteolysis Putative SUMO-1 pathway10	9.4	MDM2, JUN, NR3C1, RELA, TP53, TOP2A
24	Proteolysis_Putative SUMO-1 pathway41	9.4	TP53, FAS, MDM2, JUN, RELA, NR3C1
25	Apoptosis and survival TNFR1 signaling pathway10	9.3	CASP10, CASP9, CASP3, JUN, BAX, RELA
26	MIF Mediated Glucocorticoid Regulation36	9.3	BCL2, BAX, MIF, IL3, IL6, IL8
27	Glucocorticoid Receptor Signaling36	9.2	NR3C1, IL3, POLR2A, TAF15, BCL2, BAX
28	DHA Signaling36	9.2	PDGFA, CASP9, CASP3, CASP10, IL3, FLT1
29	MAPK Signaling36	9.2	FLT1, JUN, ATF1, ATF6, CEBPB, BCL2
30	Transcription_P53 signaling pathway41	9.2	RELA, BCL2, VEGFA, TP53, KDR, CDK2
31	p53 Signaling36	9.1	THBS1, TP53, CASP9, CASP3, CASP10, CDK4
32	Rho Family GTPases36	9.1	VIM, KDR, BCL2, BAX, TNC, KIT
33	Pancreatic Adenocarcinoma36	9.0	CDK2, CDK4, FLT1, IL3, MDM2, CCND2
34	Apoptosis and survival FAS signaling cascades10	9.0	CASP9, CASP3, CASP10, FAS, BAX, PARP1
35	TGF-Beta Pathway36	9.0	FLT1, IL3, IL6, JUN, IL8, KDR
36	Apoptosis and survival_FAS signaling cascades41	9.0	BCL2, PARP1, BAX, FAS, CASP10, CASP9
37	Apoptosis and survival_TNFR1 signaling pathway41	8.9	BAX, CASP9, CASP3, JUN, BCL2, RELA
38	PAK Pathway36	8.9	KDR, KIT, BCL2, FLT1, CASP9, PDGFA
39	p53 Mediated Apoptosis36	8.9	TP53, PDGFA, CXCL12, PGF, KDR, CASP9
40	MIF Regulation of Innate Immune Cells36	8.8	CXCL12, CSF3, BCL2, BAX, TP53, CCL2
41	JNK Pathway36	8.8	BAX, PGF, CXCL12, TP53, IL6, KIT
42	p53 signaling pathway20	8.7	BAX, MDM2, FAS, CCND2, CASP9, TP53
43	Apoptosis Signaling Pathways37	8.7	FAS, BCL2, TP53, CASP9, CASP3, CASP10
44	p38 Signaling36	8.5	KIT, KDR, CCL2, PGF, CSF3, CXCL12
45	Antioxidant Action of Vitamin-C36	8.5	IL3, FLT1, PGF, SLC2A4, CSF3, KIT
46	Apoptosis20	8.5	TP53, BAX, BCL2, CASP9, RELA, IL3
47	Mitochondrial Apoptosis36	8.5	IL6, BAX, CDKN2A, IL3, BAK1, PGF
48	Cellular Apoptosis Pathway36	8.5	IL6, CDKN2A, KDR, PGF, CXCL12, PDGFA
49	Molecular Mechanisms of Cancer36	8.1	CASP3, WNT1, CXCL12, PRG4, PDGFA, TP53
50	Pathways in cancer20	8.0	WNT1, VEGFA, RB1, RET, RELA, NOS2

Compounds related to liposarcoma according to GeneDecks:

(show top 50)    (show all 348)

id	Compound	Score	Top Affiliating Genes
1	egcg32	10.3	CDK2, FASN, CASP9, DDIT3
2	sp 60012532 42	11.1	CASP3, TP53
3	rapamycin32 42	11.0	KIT, RB1, VIM, VEGFA, KDR, CDK2
4	glucose32	10.0	KIT, GCGR, BAK1, CFD, ATF1, CDK4
5	agar32	9.7	RET, RB1, VIM, RARA, MUC1, CDK2
6	n acetylcysteine32	9.5	KDR, CEBPB, CDKN2A, CDK4, IL3, CCND2
7	sterol32	9.4	LRP1, LIPE, CEBPZ, CETP, MSBP1, ATF6
8	phosphatidylserine32 9 9	11.3	VIM, LPL, PARP1, BCL2, BAK1, CDK2
9	nitric oxide32 9 18 9	12.2	KIT, RB1, LIPE, KDR, MUC1, CEBPB
10	steroid32	9.1	KIT, RB1, RARA, LIPE, YBX1, S100A4
11	cysteine32	9.1	LRP1, RARA, PARP1, KDR, MUC1, BAK1
12	ly29400232	9.0	RET, VEGFA, RARA, JUN, IL6, IL8
13	ciglitazone32	8.9	RARA, PARP1, BAX, JUN, IL6, IL8
14	progesterone32 42 9 18 9	12.9	KIT, RB1, RARA, BCL2, MVP, CEBPB
15	mifepristone32 42 9 9	11.8	MUC1, BAX, JUN, CDK2, IL8, FASN
16	sb 20358032 42	9.8	RB1, VIM, VEGFA, PARP1, BCL2, ATF1
17	fatty acid32	8.6	LRP1, GCGR, LIPE, CFD, MSBP1, CDKN2A
18	n-(4-hydroxyphenyl)retinamide32	8.5	RB1, VIM, RARA, PARP1, BCL2, BAX
19	mg 13232 42	9.4	RARA, PARP1, KDR, BAX, CEBPB, JUN
20	carboplatin32 34 9 9	11.4	RB1, VEGFA, PARP1, KDR, BCL2, MSH2
21	doxorubicin32 34 9 9	11.3	KIT, VIM, PARP1, KDR, MVP, BAK1
22	flavopiridol32 9 9	10.3	KIT, RB1, VEGFA, PARP1, BCL2, BAK1
23	triptolide32	8.3	VEGFA, PARP1, BCL2, BAX, JUN, IL6
24	vitamin d32	8.2	LRP1, VIM, LPL, RARA, CEBPB, JUN
25	troglitazone32 42 9 9	11.2	RB1, LPL, RARA, BCL2, BAK1, BAX
26	oligonucleotide32	8.2	LRP1, RET, KIT, GCGR, RB1, VIM
27	thymidylate32	8.1	RB1, VIM, VEGFA, BCL2, MVP, BAX
28	resveratrol32 9 18 9	11.1	RB1, VEGFA, PARP1, BCL2, BAK1, BAX
29	pd 98,05932	7.8	RET, KIT, RB1, RARA, PARP1, BCL2
30	estrogen32	7.8	LPL, RARA, LIPE, KDR, YBX1, S100A4
31	phosphatidylinositol32	7.7	LRP1, RET, KIT, RB1, RARA, KDR
32	testosterone32 9 18 9	10.6	RELA, RET, KIT, RB1, VIM, LPL
33	docetaxel32 34 9 9	10.6	KIT, VEGFA, PARP1, KDR, BCL2, MVP
34	oxygen32 18	8.5	RB1, LIPE, PARP1, BCL2, BAK1, BAX
35	tamoxifen32 34 9 9	10.4	VIM, VEGFA, LPL, RARA, KDR, BCL2
36	camptothecin32 42 9 9	10.4	RB1, PARP1, KDR, BCL2, MVP, BAK1
37	thymidine32 18	8.3	KIT, RB1, RARA, KDR, MUC1, JUN
38	cytarabine32 34 9 9	10.0	KIT, RB1, VIM, BCL2, MVP, MUC1
39	adriamycin32	7.0	RB1, VIM, BCL2, MVP, MUC1, BAX
40	tyrosine32	6.8	LRP1, RET, KIT, RB1, VEGFA, RARA
41	paraffin32	6.8	RELA, RET, KIT, RB1, VIM, VEGFA
42	paclitaxel32 34 9 9	9.7	KIT, RB1, VIM, VEGFA, RARA, PARP1
43	5fluorouracil32	6.6	KIT, RB1, VEGFA, KDR, BCL2, MVP
44	actinomycin d32	6.5	KIT, RB1, VIM, VEGFA, RARA, PARP1
45	genistein32 9 18 9	9.3	RET, RB1, VIM, VEGFA, LPL, PARP1
46	cisplatin32 34 9 9	9.3	RB1, VEGFA, PARP1, KDR, BCL2, MVP
47	dexamethasone32 42 34 9 9	9.9	LRP1, LRPAP1, RB1, VIM, VEGFA, LPL
48	vegf32	5.7	LRP1, RET, KIT, PARP1, KDR, BCL2
49	cycloheximide32	5.5	KIT, VIM, VEGFA, LPL, RARA, PARP1
50	serine32	5.0	LRP1, LRPAP1, RELA, RET, KIT, RB1

Cellular components related to liposarcoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein kinase holoenzyme complex	GO:000307	10.2	CDK2, CDK4, CCND2
2	platelet alpha granule lumen	GO:031093	10.0	THBS1, PDGFA, F13A1, CFD, VEGFA
3	nuclear chromatin	GO:000790	9.8	RXRA, SMARCA4, NR1H3, TP53, CEBPB, MUC1
4	external side of plasma membrane	GO:009897	9.4	SLC2A4, CXCL12, THBS1, FAS, CD34, CD36
5	extracellular space	GO:005615	8.7	CCL2, TNC, CRP, PDGFA, THBS1, CXCL12
6	extracellular region	GO:005576	8.2	TNC, F13A1, AMBP, CCL2, FAS, PTX3
7	nucleoplasm	GO:005654	8.1	TP53, DDIT3, SRSF10, PPARG, PPARA, NR1H2
8	cytoplasm	GO:005737	5.7	NR3C1, NR1H3, NR1H2, PPIAL4C, SRSF10, DDIT3
9	cytosol	GO:005829	5.7	CASP10, CASP3, CASP9, TP53, PPARG, NR3C1
10	nucleus	GO:005634	4.5	ADAD1, NOS2, PLAG1, CREB3L3, CREB3L2, SMARCA4

Biological processes related to liposarcoma according to GeneDecks:

(show all 48)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cholesterol storage	GO:010887	10.7	NR1H3, NR1H2, PPARA, PPARG
2	lipid homeostasis	GO:055088	10.7	ACACA, NR1H3, PPARG, CETP
3	negative regulation of interferon-gamma-mediated signaling pathway	GO:060336	10.6	NR1H3, NR1H2, PPARG
4	vascular endothelial growth factor receptor signaling pathway	GO:048010	10.6	PGF, CCL2, FLT1, KDR, VEGFA
5	organ regeneration	GO:031100	10.6	AFP, WNT1, CXCL12, PPARG, CCL2, BAK1
6	apoptotic cell clearance	GO:043277	10.5	NR1H3, CD36, RARA, LRP1
7	positive regulation of fibroblast proliferation	GO:048146	10.5	WNT1, PDGFA, MIF, CDK4, JUN
8	positive regulation of MAPK cascade	GO:043410	10.3	PDGFA, DUSP19, IL6, FLT1, CD36, KDR
9	positive regulation of endothelial cell proliferation	GO:001938	10.3	PGF, CXCL12, CCL2, JUN, KDR, VEGFA
10	transcription initiation from RNA polymerase II promoter	GO:006367	10.2	POLR2L, POLR2A, THRA, RXRA, NR3C1, NR1H3
11	negative regulation of macrophage derived foam cell differentiation	GO:010745	10.1	CRP, NR1H3, NR1H2, PPARA, PPARG, CETP
12	response to organic cyclic compound	GO:014070	10.1	ACACA, RXRA, CCND2, JUN, ATF1, MSH2
13	response to hydrogen peroxide	GO:042542	10.1	DDIT3, TRPA1, MB, JUN, BAK1, BCL2
14	lipid metabolic process	GO:006629	10.0	THRSP, PPARA, PPARG, APOC1, CD36, CETP
15	activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c	GO:008635	10.0	CASP9, CASP3, BAX, BAK1
16	female pregnancy	GO:007565	10.0	PGF, RXRA, AMBP, FLT1, BCL2, LIPE
17	positive regulation of cell proliferation	GO:008284	10.0	MDM2, PDGFA, TSPAN31, CSF3, PGF, WNT1
18	response to radiation	GO:009314	9.9	CXCL12, NR3C1, JUN, BCL2, KIT
19	cell cycle arrest	GO:007050	9.9	THBS1, DDIT3, TP53, IL8, INHA, CDKN2A
20	platelet degranulation	GO:002576	9.9	THBS1, PDGFA, F13A1, CD36, CFD, VEGFA
21	inflammatory response	GO:006954	9.9	NFKBIZ, RXRA, CRP, PTX3, CCL2, IL8
22	response to ethanol	GO:045471	9.9	SLC2A4, ACTC1, RXRA, CCND2, CCL2, BAK1
23	response to UV-B	GO:010224	9.9	MSH2, BCL2, RELA
24	aging	GO:007568	9.8	TOP2A, RXRA, NR3C1, DDIT3, CCL2, FAS
25	cellular lipid metabolic process	GO:044255	9.8	ACACA, RXRA, NR1H3, NR1H2, PPARA, GPD1
26	ovarian follicle development	GO:001541	9.8	CCND2, INHA, BAX, BCL2, KDR, KIT
27	regulation of protein heterodimerization activity	GO:043497	9.8	BAX, BAK1, BCL2
28	cellular response to lipopolysaccharide	GO:071222	9.8	NOS2, NR1H3, CCL2, IL8, CD36
29	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.7	TP53, IL6, IL3, MIF, CD36, VEGFA
30	regulation of protein homodimerization activity	GO:043496	9.7	BAX, BAK1, BCL2
31	B cell homeostasis	GO:001782	9.7	CASP3, BAX, BAK1, BCL2
32	positive regulation of neuron apoptotic process	GO:043525	9.5	BAX, JUN, CASP3, CASP9, NR3C1
33	negative regulation of transcription, DNA-dependent	GO:045892	9.5	HMGA2, TP53, PPARG, NR1H2, SMARCA4, THRA
34	negative regulation of transcription from RNA polymerase II promoter	GO:000122	9.5	PPARA, NR1H3, SMARCA4, RXRA, PRRX1, PPARG
35	response to gamma radiation	GO:010332	9.5	TP53, CCL2, BAX, BAK1, BCL2
36	response to hypoxia	GO:001666	9.4	CRP, NOS2, THBS1, CXCL12, PGF, PPARA
37	negative regulation of apoptotic process	GO:043066	9.3	WNT1, CXCL12, THBS1, TP53, HMGA2, CASP3
38	signal transduction	GO:007165	9.3	ERG, TNC, PPARG, NR3C1, PKP1, PRKG1
39	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.3	PPARG, PPARA, NR1H2, NR1H3, SMARCA4, RXRA
40	neuron apoptotic process	GO:051402	9.2	TP53, CASP3, FAS, BAX, BCL2, RB1
41	positive regulation of apoptotic process	GO:043065	9.2	TOP2A, RXRA, DDIT3, TP53, HMGA2, FAS
42	anti-apoptosis	GO:006916	9.2	NR3C1, CCL2, FAS, CEBPB, MUC1, BCL2
43	induction of apoptosis by intracellular signals	GO:008629	9.1	TP53, CASP9, CASP3, BAX, BAK1, BCL2
44	response to drug	GO:042493	9.1	LPL, PGF, THBS1, TOP2A, ACTC1, ACACA
45	positive regulation of transcription, DNA-dependent	GO:045893	9.1	TP53, PPARG, PPARA, NR1H3, SMARCA4, CREB3L2
46	release of cytochrome c from mitochondria	GO:001836	9.0	TP53, CASP3, JUN, BAX, BAK1, BCL2
47	induction of apoptosis	GO:006917	9.0	THBS1, PPARG, CASP3, CASP10, FAS, INHA
48	response to DNA damage stimulus	GO:006974	8.6	TOP2A, DDIT3, TP53, CASP9, CASP3, BAX

Molecular functions related to liposarcoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	steroid hormone receptor activity	GO:003707	10.3	THRA, RXRA, NR1H3, NR1H2, PPARA, PPARG
2	ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity	GO:004879	10.3	RXRA, NR1H3, NR1H2, PPARA, PPARG
3	cAMP response element binding	GO:035497	9.9	CREB3L2, HMGA2, JUN
4	double-stranded DNA binding	GO:003690	9.9	YBX1, MSH2, JUN, NR3C1, RXRA, TARDBP
5	growth factor activity	GO:008083	9.8	PGF, CSF3, CXCL12, PDGFA, IL6, IL3
6	transcription regulatory region DNA binding	GO:044212	9.5	WNT1, THRA, RXRA, CREB3L2, NR1H3, PPARG
7	sequence-specific DNA binding	GO:043565	9.5	NR3C1, CREB3L2, CREB3L3, RXRA, TSN, TOP2A
8	enzyme binding	GO:019899	9.4	SLPI, CSF3, TOP2A, RXRA, PPARG, TP53
9	protein heterodimerization activity	GO:046982	9.0	NR1H3, NR3C1, RXRA, PDGFA, TYR, TOP2A
10	transcription factor binding	GO:008134	8.9	CD34, HMGA2, TP53, DDIT3, THRA, CDKN2A
11	sequence-specific DNA binding transcription factor activity	GO:003700	8.7	DDIT3, PPARG, PPARA, NR3C1, CREB3L2, CREB3L3
12	DNA binding	GO:003677	8.7	TP53, DDIT3, PPARG, PPARA, NR1H2, NR1H3
13	protein homodimerization activity	GO:042803	8.4	NR3C1, CRP, NOS2, PDGFA, TYR, TOP2A
14	identical protein binding	GO:042802	7.9	MDM2, FAS, TP53, THBS1, PRC1, FLT1
15	protein binding	GO:005515	2.5	WNT1, CRP, CREB3L3, SMARCA4, NR3C1, NR1H3